After dropping to its lowest valuation at the end of September, the BioWorld Neurological Diseases index, a price-weighted index of public biopharmaceutical companies that are focused on developing therapies to treat neurological diseases, got on a roll and climbed 22% during the next two months. However, a surprising trial failure reported by Sage Therapeutics Inc. last week served to eat into those index gains.

The top 10 biopharma stock gainers and losers for the week.

Biopharma money raised to-date and by quarter in 2019, including public, private and other financings.